We're always one variant behind the virus
Existing Ebola vaccines cannot protect against the Bundibugyo ebolavirus strain driving the current outbreak. CEPI has awarded $1.9m to Public Health Vaccines to accelerate development of a Bundibugyo-specific vaccine.
- Bundibugyo ebolavirus is not covered by existing Ebola vaccines
- CEPI awarded $1.9 million to Public Health Vaccines for vaccine development
- Current outbreak spreading with no preventive vaccine available
- Existing vaccines designed for Zaire ebolavirus strain
An Ebola outbreak caused by the Bundibugyo strain requires new vaccine development as existing vaccines prove ineffective. Scientists and health organizations are racing to test treatments and accelerate vaccine development.
The vaccines that have protected people against Ebola for years are useless against what is spreading now. The outbreak unfolding is caused by Bundibugyo ebolavirus, a strain that existing inoculations cannot stop. Scientists and public health officials are moving with urgency to develop a new vaccine, but they are starting from behind—racing to catch up to a virus that is already moving through communities.
The Bundibugyo strain is not new to science, but it has remained relatively rare compared to other Ebola variants. The vaccines currently available were designed to protect against Zaire ebolavirus, the strain responsible for the devastating 2014-2016 West African outbreak that killed more than eleven thousand people. Those vaccines work well for their intended target. They do not work here. This gap between what we have and what we need has created an immediate crisis: people are falling ill with a disease we can treat only symptomatically, while the clock runs on vaccine development.
The Coalition for Epidemic Preparedness Innovations, known as CEPI, has committed $1.9 million to Public Health Vaccines to accelerate the creation of a Bundibugyo-specific vaccine. This is not a small amount of money, but it is also not the kind of unlimited funding that would suggest this problem is solved. The award represents a decision to prioritize this particular threat, to move it up the queue of work happening in laboratories around the world. Public Health Vaccines now has resources to push forward faster than they could have otherwise. The question is whether faster will be fast enough.
What makes this moment different from previous Ebola responses is the mismatch between our tools and the threat. In 2014, when Zaire ebolavirus emerged in West Africa, there was no vaccine at all. Scientists had to develop one from scratch while the outbreak spread. This time, we have proven vaccine technology—we know how to make these things work. But we have to remake it for a different target. The science is not starting from zero, but the clock is still running, and every week the outbreak continues is a week in which people are exposed to a virus we cannot yet prevent.
The broader implication is uncomfortable: our pandemic preparedness systems are built around known threats. We have vaccines for the Ebola strains we have seen before. We have treatment protocols for the variants we have studied. But the virus does not read our playbook. Bundibugyo ebolavirus was always there, always capable of causing human disease, but it remained peripheral to our planning. Now it is central, and we are improvising. The race to develop a new vaccine is not just about stopping this outbreak—it is a test of whether we can adapt fast enough when the next unexpected variant emerges. The answer will determine how many people get sick before we catch up.
Citas Notables
Scientists and health organizations are racing to test treatments and accelerate vaccine development as the outbreak widens— Scientific American / The New York Times reporting
La Conversación del Hearth Otra perspectiva de la historia
Why can't the existing vaccines just be modified quickly? Don't we already know how to make Ebola vaccines?
We do know how to make them, and that's actually the advantage here. But a vaccine designed for one strain doesn't automatically protect you from another. It's like having a key that opens one lock perfectly—it won't open a different lock, even if the locks are similar. We have to design a new key.
So the $1.9 million is meant to speed that up?
Yes, but it's also an acknowledgment that we're behind. That money accelerates the work, but it doesn't eliminate the time it takes to develop, test, and manufacture a vaccine. We're talking months at best, and the outbreak is happening now.
What happens to people who get sick while we're waiting?
They get supportive care—fluids, blood transfusions, management of symptoms. Some survive, some don't. The survival rate depends on how quickly they get to a hospital and how severe their infection is. But there's no specific treatment that stops the virus itself.
Is Bundibugyo more dangerous than the strains we've dealt with before?
We don't have enough data yet to say it's more lethal, but it's spreading in a population with no immunity and no vaccine protection. That's what makes it dangerous—not necessarily the virus itself, but the fact that we're unprepared for it.
What does this tell us about the next outbreak?
That we're always one variant behind. We prepare for the last crisis, not the next one. Until we can develop vaccines faster, or keep a broader arsenal ready, we'll keep finding ourselves in this position—scrambling to catch up.